BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Merck Canada Inc. Puts $12.5 Million Into Montreal Research Centers


11/29/2012 7:40:47 AM

Merck Canada has announced a $12.5 million investment in basic and translational research at three university-affiliated and hospital-based research centres in Montreal, Québec. The three beneficiaries are the Research Institute of the McGill University Health Centre (RI-MUHC), the CHUM Research Centre (CRCHUM), and the Montréal Heart Institute Research Centre (MHI). The investment reflects a shift to outsourcing in Merck’s research commitment to the Quebec province, in line with broader industry trends. Canada’s life sciences heartland has been feeling the pinch of job cuts and facility closures in recent years, as pharmaceutical companies seek cost-efficiencies in their global R&D operations. Merck Canada itself said in July 2010 that it would be phasing out operations at the Merck Frosst Centre for Therapeutic Research in Kirkland, west of Montreal, as part of a previously-announced restructuring following Merck & Co’s merger with Schering-Plough. At the same time, though, came a pledge to inject $100 million over five years in biopharmaceutical research and development in Québec. This week’s announcement is the latest contribution to that programme.


 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES